Reducing Clinical Trial Burdens Brings Greater Participant Diversity – PhRMA
Executive Summary
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.
You may also be interested in...
How Do You Build A Clinical Trial Network Focused On Diversity?
Stakeholders discuss network models, barriers to their creation, and what is needed for them to be successful at PhRMA meeting.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
NCI’s Clinical Trial Accrual Is ‘Better’ Than Pharma Industry’s, Director Sharpless Says
NCI networks had vast under accrual in the past year, but Sharpless says industry has been affected to a greater degree. He says the institute also has been better at accruing minority patients.